TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00906334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: The original dosing regimen was 800 mg/m\^2 ON 01910.Na.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
Study: NCT04383223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTransition
Description: Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTransition
Description: Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
Study: NCT02648932

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Haplo-Cord Transplant
Description: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Matched Unrelated Donor Transplant
Study: NCT04001127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Functional Training
Description: The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing).
Study: NCT00054665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Description: 1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Description: 1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Study: NCT00982137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever virus; Live attenuated Japanese encephalitis virus
Description: STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus; Yellow fever virus
Description: ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
Study: NCT02702284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Directives
Description: These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Directives
Description: These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advance Directives without assistance
Description: This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advance Directives without assistance
Description: This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
Study: NCT00895908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship Group
Description: Social skills training for 30 sessions, held twice per week over 4 to 5 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic tutoring
Description: Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
Study: NCT00351390

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug therapy for HF
Description: Titration of HF meds in an aggressive out patient manner following guideline direction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NT-proBNP guided HF therapy
Description: Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP \<1000 pg/mL
Study: NCT00794469

Intervention type: OTHER
Intervention: Water
Description: Children will drink 10 cc/kg of cold water(4 degrees centigrade)
Study: NCT02853123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: fixed dose combination once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: fixed dose combination once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study: NCT00902057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: single desmopressin subcutaneous injection, 1.5mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: single desmopressin subcutaneous injection, 3mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: single desmopressin subcutaneous injection, 15mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline subcutaneous
Study: NCT00564603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate Injection
Description: Dexamethasone, 10mg, continuously infused up to 48h after surgeries.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Saline, in same volume of 2mL
Study: NCT00839436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Study: NCT02365805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
Description: Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin + Cisplatin + Fluorouracil
Description: Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Ciclofosfamide
Description: Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
Study: NCT01116349

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate and screws or nailing
Description: Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hanging Support System (HSS) brace
Description: Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
Study: NCT04427228

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiosurgery Single Treatment
Description: Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) \< 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
Study: NCT04332471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Stretching and ice massage
Study: NCT00982137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus; Yellow fever virus
Description: Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
Study: NCT03922503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)
Description: In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)
Description: After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
Study: NCT02387398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Angiography
Description: Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
Study: NCT02421432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Laparoscopy-assisted transanal total mesorectal excision
Study: NCT03967652

Intervention type: DIAGNOSTIC_TEST
Intervention: Nanomaterial-based sensors
Description: Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nanomaterial-based sensors
Description: Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nanomaterial-based sensors
Description: Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
Study: NCT00649324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide Tablets 50 mg
Description: 50mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide Tablets (50 mg
Description: 50mg, single dose fasting
Study: NCT00025493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT04034485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: PCSK9 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evolocumab
Description: PCSK9 inhibitor
Study: NCT00948701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Forward Together 2
Description: RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moving Forward Together 2
Description: RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
Study: NCT01925105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Optimization of treatment
Description: Optimization of treatment of diseases and symptoms
Study: NCT04427228

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery Three Treatments
Description: Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
Study: NCT02379871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Supine mid-thoracic spinal manipulation to the T4/5 region

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
Study: NCT04177160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects sit still and listen to preferred music for 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects sit still and listen to preferred music for 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White noise
Description: Subjects sit still and listen to white noise for 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White noise
Description: Subjects sit still and listen to white noise for 5 minutes.
Study: NCT00054665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
Study: NCT02074397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distant extrafascial injection
Study: NCT00054665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
Study: NCT02074397

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subfascial injection
Study: NCT00054665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
Study: NCT01337258

Intervention type: DRUG
Intervention: Dutasteride
Description: dutasteride 0.5mg daily.
Study: NCT03756870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
Study: NCT01337258

Intervention type: DRUG
Intervention: Placebo
Description: Men taking placebo daily
Study: NCT00424840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Description: Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2
Study: NCT02932670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: costoclavicular nerve block
Description: ultrasound-guided costoclavicular nerve block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: costoclavicular nerve block
Description: ultrasound-guided costoclavicular nerve block
Study: NCT00003746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-chlorodeoxyadenosine (CDA) daily
Description: Daily administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-chlorodeoxyadenosine weekly
Description: Weekly administration
Study: NCT00943059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cellulosum Mycrocryst
Description: Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
Study: NCT03216889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
Study: NCT04569266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercise rehabilitation treatment
Description: Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment).

Intervention type: OTHER
Group type: OTHER
Intervention: No specific exercise rehabilitation treatment
Description: Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment).
Study: NCT03879707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Melatonin is known to induce sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium 500Mg Oral Tablet
Description: Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
Study: NCT03468153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Description: Patient-derived dual specificity CD19 and CD22 CAR-T Cells
Study: NCT02449655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD2014
Description: AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
Study: NCT02948972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete surgery
Description: complete surgery of colorectal deep infiltrating endometriosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In vitro fertilization without surgery
Description: IVF without endometriosis surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In vitro fertilization without surgery
Description: IVF without endometriosis surgery
Study: NCT02906618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3C 15N 2H-LY3039478 IV
Description: Administered IV
Study: NCT02370160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT2219ARL
Description: DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
Study: NCT00823368

Intervention type: DRUG
Intervention: STX209

Intervention type: DRUG
Intervention: STX209
Study: NCT00424840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m2
Description: Level II (every 21 day cycle, D8), 1.6 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.8 mg/m2
Description: Level III (every 21 day cycle, D8) 1.8 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: Carboplatin AUC6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: Carboplatin AUC6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: Carboplatin AUC6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg